Targeting this PTM network presents a promising strategy for next-generation therapies that selectively inhibit viral infection while preserving BA transport, overcoming the limitations of conventional inhibitors that indiscriminately disrupt virus-NTCP interactions. The gene discussed is SLC10A1; the disease is viral infectious disease.